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Human West Nile
Virus, France 
To the Editor: West Nile virus
(WNV) is a mosquito-transmitted fla-
vivirus, widely distributed in Africa,
the Middle East, Asia, and southern
Europe. Since the 1990s, its geo-
graphic distribution has expanded and
caused epidemics of meningoen-
cephalitis (1). Recently introduced
into the United States, it expanded
rapidly from New York throughout
the country and caused illness in
9,862 human patients in 2003 (2). In
France, the first reported WNV out-
break that affected horses and humans
occurred during the summer of 1962
in the Camargue region (1). After
1965, no human or equine WNV
infections were reported until
September 2000, when a large out-
break of equine encephalitis occurred
in France (3). No human cases were
reported at that time. In September
2003, a human living in Fréjus
(Département du Var, southeastern
France) was diagnosed with acute
WNV infection in Nice University
Hospital. At the same time, an equine
case was diagnosed 20 km from the
patient’s home; consequently, public
health authorities initiated a retro-
spective study of patients hospitalized
in the French Mediterranean region in
which viral meningoencephalitis was
suspected. We report four human
cases from Fréjus Hospital.
Twenty patients who had been hos-
pitalized at some time from August 1
to October 15, 2003, for febrile
meningitis, encephalitis, or poly-
radiculoneuritis were screened. Four
patients in whom cerebrospinal fluid
(CSF) analysis indicated a viral cause
were included. In addition, serum
samples from two patients who had
experienced flulike symptoms with
exanthema during the same period
were tested further. Serologic diagno-
sis of acute WNV infection was based
on immunoglobulin (Ig) M-capture
and direct IgG enzyme-linked
immunosorbent assay followed by
80% plaque reduction neutralization
titer (PRNT80) by using the France
2000 WNV strain (3).
Patient 1, 46 years old, and patient
2, 25 years old, had a flulike syn-
drome with maculopapular exanthe-
ma; WNV seroconversion was seen
on a pair of sera collected on days 3
and 16 for patient 1, and days 3 and 12
for patient 2, after onset of fever.
Patients 3 and 4 had meningoen-
cephalitis with maculopapular exan-
thema. In patient 3, a fourfold
increase in WNV neutralizing anti-
bodies was seen in serum samples on
2 consecutive days (days 3 and 15
after onset of fever). In patient 4,
WNV IgM antibodies were detected
in CSF (day 4 after onset of fever),
and neutralizing antibodies (titer =
160) were reported in a serum speci-
men on day 75. Attempts to detect
WNV RNA by reverse transcrip-
tion–polymerase chain reaction, or to
isolate the virus from serum speci-
mens in patients 1 and 2 and CSF in
patient 4, were negative because of
the low level and short duration of
WNV viremia (4). All patients recov-
ered.
On the basis of serologic results,
we describe the first human clinical
WNV infections in France since 1964
(5). The four patients lived in the
same city, had not traveled, and had
an onset of their illness during the last
week of August 2003. Of note, four
clinical infections were identified, but
many more WNV subclinical and
asymptomatic infections likely
occurred simultaneously.
After the reemergence of WNV in
horses in the Camargue region in
2000, surveillance on sentinel birds
(ducks and chickens) showed a low
circulation of WNV in 2001 and 2002
in this area. Meanwhile, no clinical
human or equine cases were detected.
During the summer of 2003, WNV
reemerged in humans 200 km east of
Camargue, in the Département du Var,
along the Mediterranean coast. ALETTERS
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study conducted on French blood
donors from September to November
2000 showed low titers of WNV neu-
tralizing antibodies in two donors
originating from the Département du
Var (6). However, to date, no clinical
human cases have been reported in
this area.
WNV must be considered as a
causative agent of meningitis,
encephalitis, and polyradiculoneuritis
during summer and early fall in south-
ern France. Given the capacity of
WNV to cause large outbreaks, the
surveillance will be extended to the
entire Mediterranean coastal area.
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SARS in Teaching
Hospital, Taiwan
To the Editor: During the global
epidemic of severe acute respiratory
syndrome (SARS), the illness was
transmitted rapidly within hospitals,
which created pools of persons who
became infected and through whom
the disease was spread. Intrahospital
transmission amplified regional out-
breaks and augmented spread of the
illness into the community (1–3).
Healthcare workers, hospital patients,
and hospital visitors accounted for
18%–58% of all cases of SARS in the
five countries with the largest out-
breaks (1,2). The concentration of
SARS among hospital staff strained
hospital facilities, personnel, and
finances. 
National Taiwan University
Hospital, established more than 100
years ago, is the first teaching hospital
and the best resource in Taiwan for
managing patients with illnesses that
are difficult to treat. The hospital has
2,400 beds and provides primary and
tertiary care services in Taipei. Taipei
City was among the hardest hit areas
by SARS in the world (3). From
March 10 to July 23, 2003, the hospi-
tal reported 270 patients with SARS,
many of whom were severely ill. The
hospital treated 180 of the 665
patients with SARS reported in
Taiwan, even though it was staffed by
4,450 of the country’s 178,000 health-
care workers. SARS had an impact on
this hospital for three likely reasons.
First, the hospital identified and treat-
ed the first SARS patients in Taiwan
(4,5). Second, it provided easy access
through the emergency room and out-
patient clinics. Febrile persons with a
travel history to SARS-affected areas
or other risk of SARS exposure came
directly to this hospital for care.
Third, many hospitals, particularly
private facilities, were reluctant to
report and admit patients with SARS
during the early stage of the epidemic
because of financial considerations
and fear. 
The hospital felt the brunt of the
epidemic in Taiwan during early May
2003, which paralleled the severity of
the SARS epidemic in Taipei (3,4,6).
The maximal number of SARS
patients admitted to the hospital with-
in 24 hours was 12 on May 3. The
maximal number of SARS patients
reported within 24 hours was 15 on
May 6; 8 patients were transferred to
other hospitals on May 7. However,
18 patients stayed overnight in the
emergency room on May 7.
Subsequently, SARS developed in 12
emergency room healthcare workers
(6,7).
Our preliminary studies showed
that the average inpatient cost for
patients with SARS was not higher
than for patients with pneumonia,
after adjustment for age, sex, and
length of stay (MF Chen, unpub.
data). However, SARS caused finan-
cial and operational disruptions in the
hospital. During this period, hospital
utilization rates decreased. Compared
with the previous year’s rates, outpa-
tient and emergency visits fell to 37%,
inpatient admissions fell to 29%, and
surgical procedures fell to 15%. Bed
occupancy decreased from 86% in
May 2002 to 38% in May 2003.